Piscataway, NJ - Sabinsa Corporation Senior Executive Vice President, Mark C. Sysler announced today that a Final Judgment has been entered in the patent infringement lawsuit the company filed against Indfrag, Ltd. of India.

The action was commenced in the United States District Court in New Jersey by Sabinsa, which sought relief for patent infringement by Indfrag under Sabinsa’s US Patent # 5,804,596 entitled "Method of Preparing a Forskolin Composition from Forskohlin Extract and Use of Forskohlin for Promoting Lean Body Mass and Treating Mood Disorders".

The final judgment filed with the Court finds that "…the ...Patent is valid and was properly issued by the United States Patent and Trademark Office under the Patent Laws of the United States", and that "Indfrag and its agents … are enjoined from importing into the United States, marketing, advertising for sale or selling in the United States any Coleus forskohlii extract whose forskohlin content is above 3%...."

Sysler commented that, "We are encouraged by the results our efforts are having regarding protection of our ForsLean® patent for our licensed customers. This judgment is significant in that it establishes a precedent to keep manufacturers from making the material and selling it in the United States in violation of patent law. As always, we encourage our industry to respect the intellectual property rights of others."

Sabinsa Corporation, which has pioneered the introduction of several Ayurvedic herbal extracts in the US market, is an application-oriented manufacturing and marketing company. Sabinsa distinguishes itself by its extensive scientific research support for its customers and products, and the scientific credentials of its key technical staff.

ForsLean® is a registered trademark of Sabinsa Corporation. US Patent #5,804,596